Immusoft
Seattle, US · Delaware corporation · 9 known investors
Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient. The company focuses on personalized protein therapeutics for patients.
Founders & leadership
MS
Matthew ScholzFounder
SA
Sean AinsworthChief Executive Officer
RS
Robert SikorskiChief Medical Officer
RH
Rob HayesChief Scientific Officer
SM
Scott McIvorChief Development Officer
RC
Richard Chin, M.D.Named on SEC filing
EG
Eric GarciaNamed on SEC filing
DL
David LowenschussGeneral Counsel
Board
MA
Mark Ahn, Ph.D.Board director
Investors · 9
BioRock VenturesSan Francisco
Boston Harbor AngelsBoston · $250K – $1.5M
Breakout VenturesSan Francisco · $500K – $6M
EQx FundBoston
Invariantes FundGuatemala City
Michigan Capital NetworkGrand Rapids
NYBC VenturesNew York
Breakout Labsreported
Also in the syndicate · 1
California Institute for Regenerative Medicine
Reported raises · per SEC filings
Form D private placements$40.5M disclosed across 6 of 7 rounds · 2014–2026
▶$4.6MraisedJun 2024 · 25 investors · OtherRule 506(b)
▶$4.6MraisedJun 2024 · 25 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Julia MooreDirector
- Sean AinsworthExecutive Officer, Director
- Matthew ScholzDirector
- Cam GallahgerDirector
- Anthony SunDirector
- Offering amount
- $10M
- Amount sold
- $4.6M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.3MraisedMar 2021 · 32 investors · OtherRule 506(b)
▶$10.3MraisedMar 2021 · 32 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Anthony SunDirector
- Julia MooreDirector
- Wendell KingDirector
- Sean c/o AinsworthExecutive Officer, Director
- Matthew ScholzDirector
- Offering amount
- $11M
- Amount sold
- $10.3M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.2MraisedJan 2019 · 64 investors · OtherRule 506(b)
▶$20.2MraisedJan 2019 · 64 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Sean AinsworthExecutive Officer, Director
- Julia MooreDirector
- Wendell KingDirector
- Anthony SunDirector
- Matthew ScholzDirector
- Rich VincentExecutive Officer
- Offering amount
- $23.4M
- Amount sold
- $20.2M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.7MraisedNov 2016 · 11 investors · OtherRule 506(b)
▶$2.7MraisedNov 2016 · 11 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Mark Ahn, Ph.D.Director
- Wendell KingDirector
- Matthew ScholzExecutive Officer, Director
- Offering amount
- $4.6M
- Amount sold
- $2.7M
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$375KraisedAug 2015 · 3 investors · BiotechnologyRule 506(b)
▶$375KraisedAug 2015 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew ScholzExecutive Officer, Director
- Mark Ahn, Ph.D.Director
- Offering amount
- $1M
- Amount sold
- $375K
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedAug 2014 · 11 investors · BiotechnologyRule 506(b)
▶$2.4MraisedAug 2014 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard Chin, M.D.Director
- Eric GarciaExecutive Officer
- Matthew ScholzExecutive Officer, Director
- Mark Ahn, Ph.D.Director
- Offering amount
- $3.3M
- Amount sold
- $2.4M
- First sale
- Aug 2014
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Immusoft went on to found or lead other companies.
Competitors · 6
by search overlapInmune Bio20 shared keywordsINmune Bio is a clinical-stage biotechnology company developing immunotherapies, including XPro1595, aimed at treating neurodegenerative and psychiatric diseases through a biomarker-directed approach. The company works on translating inflammatory therapies into clinical treatments for neurologic and other diseases.
Immuneering17 shared keywordsImmuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
Inimmune15 shared keywordsInimmune is a clinical-stage biotech company that discovers and develops immunotherapies based on innate immune modulation, including Toll-like receptor agonists, to treat inflammatory conditions such as allergy, cancer, and autoimmune disease. Its lead program, INI-2004, is an intranasal TLR4 agonist in Phase 2 trials for allergic rhinitis, alongside INI-4001, a TLR7/8 agonist in Phase 1 oncology trials, plus pre-clinical vaccine adjuvant work.
Imux15 shared keywordsImmunic Therapeutics is a late-stage biotechnology company developing orally administered small molecule therapies for neurologic, chronic inflammatory, and autoimmune diseases. Its clinical programs target conditions including multiple sclerosis and celiac disease.
Immunome12 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Immunai12 shared keywordsImmunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development. The company serves pharmaceutical and biotech researchers working on inflammatory and oncological therapies.
Companies competing with Immusoft for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $466.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $3.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2012 | $300K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Immusoft do?
- Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient. The company focuses on personalized protein therapeutics for patients.
- Who founded Immusoft?
- Immusoft was founded by Matthew Scholz.
- Who are Immusoft's investors?
- Immusoft's investors include BioRock Ventures, Boston Harbor Angels, Breakout Ventures, EQx Fund, Invariantes Fund, Michigan Capital Network, NYBC Ventures, Breakout Labs.
- How much funding has Immusoft raised?
- Immusoft has disclosed $40.5M raised across 6 of its 7 known rounds.
- Where is Immusoft headquartered?
- Immusoft is headquartered in Seattle, US.